Last reviewed · How we verify

Antabuse — Competitive Intelligence Brief

Antabuse (DISULFIRAM) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aldehyde Dehydrogenase Inhibitor [EPC]. Area: Metabolic.

marketed Aldehyde Dehydrogenase Inhibitor [EPC] Lysyl oxidase homolog 4 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Antabuse (DISULFIRAM).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antabuse TARGET DISULFIRAM marketed Aldehyde Dehydrogenase Inhibitor [EPC] Lysyl oxidase homolog 4 1951-01-01
disulfiram plus lorazepam disulfiram plus lorazepam University of New Mexico marketed Aldehyde dehydrogenase inhibitor plus benzodiazepine Aldehyde dehydrogenase (ALDH); GABA-A receptor
antabuse (disulfiram) antabuse (disulfiram) Psykiatrisk Center Gentofte marketed Aldehyde dehydrogenase inhibitor Aldehyde dehydrogenase (ALDH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aldehyde Dehydrogenase Inhibitor [EPC] class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antabuse — Competitive Intelligence Brief. https://druglandscape.com/ci/disulfiram. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: